References
- Jansen ET, Sørbye H, Welin S, et al. Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol. 2010;49:740–756.
- Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717–1751.
- Öberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753–781.
- Yao JC, Hassan M, Phan A, et al. One hundred years after “25 cases in the United States”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United Sttes. J Clin Oncol. 2008;26:3063–3072.
- Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain. Cancer Invest. 2005;23:182–190.
- Beuken-van Everdingen MHJ, Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–1449.
- WHO. Cancer Pain Relief. Geneva, Switzerland: World Health Organisation; 1998.
- Grond S, Zech D, Diefenbach C, et al. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64:107–114.
- Portenoy RK. Cancer pain. Epidemiology and syndromes. Neurol Clin. 1999;63:2298–2307.
- Freyhagen R, Baron R, Gockel U, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911–1920.
- Bouhassira D, Attal N, Alchaar H, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29–36.
- Beuken-van Everdingen MHJ, Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in the Netherlands. Pain. 2007;132:312–320.
- Druce MR, Bharwani N, Akker SA, et al. Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. Q J Med. 2010;103:177–185.
- Svejda B, Kidd M, Giovinazzo F, et al. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer. 2010;116:2902–2912.
- Saif MW, Larson H, Kaley K, et al. Chronic octreotide therapy can induce pancreatic insufficiency: a common but under-recognized adverse effect. Expert Opin Drug Saf. 2010;9:867–873.
- Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630–1635.
- Bennett MI, Rayment C, Hjermstad M, et al. Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain. 2012;153:359–365.
- Morris JN, Mor V, Goldberg RJ, et al. The effect of treatment setting and patient characteristics on pain in terminal cancer patients: a report from the National Hospice Study. J Chronic Dis. 1986;39:27–35.
- Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173.
- Major LF, Brown GL, Wilson WP. Carcinoid and psychiatric symptoms. South Med J. 1973;66:787–790.
- Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120.
- Li Y, Sun Y, Ma X, et al. Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression. J Tradit Chin Med. 2013;33:674–681.
- Paul-Savoie E, Potvin S, Daigle K, et al. A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin J Pain. 2011;27:529–534.
- Nekolaichuk CL, Bruera E, Spachynski K, et al. A comparison of patients and proxy symptom assessments in advanced cancer patients. Palliat Med. 1999;13:311–323.